|

Eflornithine Clinical Trials

3 actively recruiting trials across 3 locations

▲ +1 trial since May 2026

Also known as: Alpha-Difluoromethylornithine, DFMO, Difluoromethylornithine, Difluromethylornithine, difluoromethylornithine

Pipeline

Early 1: 1Phase 2: 2

Top Sponsors

  • Milton S. Hershey Medical Center1
  • Mayo Clinic1
  • Giselle Sholler1

Indications

  • Cancer3
  • Ewing Sarcoma Metastatic1
  • Diffuse Glioma1
  • Neuroblastoma1
  • Osteosarcoma1

Birmingham, Alabama1 trial

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

University of Alabama/Children's of Alabama

Phase 2

Rochester, Minnesota1 trial

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Mayo Clinic in Rochester

Early 1

Hershey, Pennsylvania1 trial

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Penn State Milton S. Hershey Medical Center and Children's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.